Sylvant® is currently licensed in EU, US and other countries worldwide including Canada, Korea and Mexico and is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with idiopathic multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. By binding to the IL-6 ligand, Sylvant® therefore blocks the signalling cascade that would lead to proliferation of immune cells.

Geographical Rights

Global

Qarziba® is currently licensed in the EU for the treatment of high risk neuroblastoma, a rare form of cancer arising from neural crest cells, in patients aged 12 months and above. The molecule is a monoclonal chimeric antibody that binds to the GD2 antigen on neuroblastoma cells, and activates an immune response that targets these cancer cells.

Country Licenced

Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK

Geographical Rights

Global

Fotivda® is a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI): an oral, once-daily inhibitor of all three vascular endothelial growth factor (VEGF) receptors. Fotivda® is indicated in the EU for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naīve following disease progression after one prior treatment with cytokine therapy for advanced RCC.

Country Licenced

Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK, Norway, Iceland, Lichtenstein

Geographical Rights

Europe, Latin America (excluding Mexico), Africa and South Africa, Australasia and New Zealand, Europe includes: Albania, Andorra, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Monaco, Montenegro, The Netherlands, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom, Vatican City, Latin America includes: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, French Guiana, Guatemala, Guyana, Honduras, Nicaragua, Panama, Paraguay, Peru, Suriname, Uruguay, Venezuela, North and South Africa includes: Algeria, Angola, Benin, Botswana, British Indian Ocean, Burkina Faso, Burundi, Cameroon, Cape Verde Islands, Central African Republic, Chad, Comoros, Congo, Democratic Republic of, Congo, Republic of, Cote d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mayotte, Morocco, Mozambique, Namibia, Niger, Nigeria, Reunion, Rwanda, Saint Helena, Sao Tome & Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, Sudan, Swaziland, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe, Australasia and New Zealand includes: Australia, Bougainville, Cook Islands, Federated States of Micronesia, Fiji

Caphosol® is indicated for the treatment and prevention of oral mucositis, a complication of cancer treatment (including radiation and chemotherapy). It contains a high concentration of phosphate and calcium ions to lubricate the mucosa of the mouth, tongue and oropharynx and help maintain the integrity of the oral cavity. Caphosol® is available as ampules or in dispersible form.

Country Licenced

Global

Geographical Rights

Global